DOCSLIB.ORG

Evidence Search Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Evidence Search Report Saskatchewan Health Authority Library https://saskhealthauthority.libguides.com/home [email protected] Regina: 306-766-4142 Saskatoon: 306-655-5224 Prince Albert: 306-765-6026 EVIDENCE SEARCH REPORT RESEARCH QUESTION: How effective are COVID-19 vaccines? UNIQUE IDENTIFIER: INF122302-01 ESR CONTEXT: Benefits following dose/second dose; how well it prevents infections; evidence of limiting viral replication or spread; preventing hospitalization; preventing ventilation; preventing “long COVID” (long term symptoms), duration of immunity (natural and vaccinated). Does not include vaccine willingness/acceptance (to be run as a separate search). RESOURCES USED: OVID Medline ClinicalTrials.gov OVID Embase Cochrane Collaboration Clinical Trials Registry PubMed & LitCovid WHO website (COVID-19 Vaccines) LIMITS/EXCLUSIONS/INCLUSIONS: REFERENCE INTERVIEW COMPLETED: December 23, 2020 DATE: December 28, 2020 LIBRARIAN: Lukas Miller REQUESTOR: Cheryl Walder & Jenny Basran TEAM: INFECTIOUS DISEASES SEARCH ALERTS CREATED: Y/N (MEDLINE, ETC.) N SUBJECTS: IMMUNITY; CLINICAL PRESENTATION; INFECTION PREVENTION & CONTROL; CITE AS: Miller, L. How effective are COVID-19 vaccines? 2020 Dec 28; Document no.: INF122302-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 26 p. (CEST evidence search report) LIBRARIAN NOTES/COMMENTS Hello, The research team acknowledged that more time is needed for global mass vaccinations to roll-out in order for there to be more quality, independent data and evidence to inform these questions. It was decided to conduct an inventory/scan of vaccine trials to support future work spurned by the rollout of vaccines. Both the Cochrane Collaboration and WHO are tracking vaccine trials and provide summary tables that includes links/URLs to relevant publications or registry entries. I have included a pared-down version of this table below. I conducted a MEDLINE search to find any publications that might comment on or inform vaccine research for COVID-19. A total of 64 citations are included below (some of which include the published trials/commentary as indicated in the COVID-NMA table). Thank you, DISCLAIMER This information is provided as a service by the Saskatchewan Health Authority and University of Saskatchewan Libraries. Professional librarians conduct searches of the literature. Results are subject to the limitations of the databases and the specificity, broadness and appropriateness of the search parameters presented by the requester. The Libraries do not represent in any matter that retrie ved citations are complete, accurate or otherwise to be relied upon. The search re sults are only valid as of the date and time at which the search is conducted. The Libraries do not accept responsibility for any loss or damage arising from the use of, or reliance on, search results. Lukas 1 SEARCH RESULTS To obtain full-text articles email [email protected]. SUMMARIES, GUIDELINES & OTHER RESOURCES COVID-NMA Initiative Vaccines: Living Mapping https://covid-nma.com/vaccines/mapping/ o Table provides a complete list of trials, drawn from the Cochrane Clinical Trial Registry and the WHO clinical trials platform. Vaccines for COVID-19 Patients (Living Evidence Synthesis) https://covid-nma.com/vaccines/ o The “Description of Primary Studies” table provides general characteristics of identified relevant RCTs, including bias assessments. o The “Trial” column includes links to trial registries and/or published journal articles for the indicated vaccine or manufacturer. World Health Organization (WHO) Draft landscape of COVID-19 candidate vaccines https://www.who.int/publications/m/item/draft- landscape-of-covid-19-candidate-vaccines o Access to downloadable spreadsheet (.xlsx) – updated twice per week. Compiles detailed information on vaccine candidates including links to trial registries and/or publications (if present). COVID-19 TRIALS Primary Studies Table (23/12/2020 update) Trial Type Comparisons Desig Participants Sample Full n size description Intervention 1 Intervention 2 NCT04412538 Inactivate KMS-1 100 EU Adjuvant RCT Healthy N=750 Full Institute of Medical d virus D0/14 Phase SARS-CoV-2 descriptio Biology (IMB), KMS-1 150 EU Adjuvant 2 serology/DNA n Chinese Academy D0/14 negative of Medical Sciences KMS-1 100 EU Adjuvant adults in tw o (CAMS). D0/28 centres in Che Y,Clin Infect KMS-1 150 EU Adjuvant China Dis,2020 D0/28 Full text Commentary NCT04470427 RNA mRNA-1273 Placebo RCT Healthy N=3035 Full ModernaTX based Phase adults w ith no 1 descriptio COVE, 2020 vaccine 3 know n history n of SARS- new CoV-2 infection in 99 centers in the US Full text Full text Commentary NCT04324606; Non ChAdOx1 MenACWY RCT Healthy N=1077 Full ISRCTN15281137; replicating Phase adults w ith no descriptio EudraCT 2020- viral 1/2 history of n 001072-15 vector laboratory University of confirmed Oxford/AstraZenec SARS-CoV-2 2 a infection or of Folegatti PM COVID-19- (COV001), Lancet, like 2020 symptoms in five centres in Full text the UK Commentary Commentary NCT04368988 Non 2 dose 25mcg Placebo RCT Healthy adult N=134 Full Novavax replicating NVX-D0/21 Phase volunteers, descriptio Keech C., N Engl J viral 2 dose 5mcg Placebo 1 SARS-CoV-2 n Med, 2020 vector NVX/M1-D0/21 infection-free Full text 2 dose 25mcg Placebo and no Commentary NVX/M1-D0/21 history of 1 dose 25mcg Placebo SARS-CoV-2 NVX/M1+Placebo infection in -D0/21 tw o centres in Australia. NCT04368728 RNA BNT162b2 Placebo RCT Healthy N=4354 Full BioNTech/Fosun based Phase SARS-CoV-2 8 descriptio Pharma/Pfizer vaccine 2/3 DNA negative n Polack FP,N Engl J adults in Med,2020 multiple centres in Full text Argentina, Commentary Brazil, Commentary Germany, Commentary South Africa, Commentary Turkey, and Commentary the USA NCT04412538 Inactivate KMS-1 D0/14 Adjuvant RCT Healthy N=192 Full The Institute of d virus KMS-1 D0/28 Adjuvant Phase adults aged descriptio Medical Biology 1 18 to 59 n (IMB), Chinese years, SARS- Academy of CoV-2 nucleic Medical Sciences acid or (CAM) antibodies Pu J, MedRxiv, negative in a 2020 single centre Full text in China. Commentary ; Commentary NCT04436276 Non Ad26.COV2.S Placebo RCT Healthy N=785 Full Janssen replicating 5x10^10vp Phase SARS-CoV-2 descriptio Pharmaceutical viral Ad26.COV2.S Placebo 1 nucleic acid n Companies vector 1x10^11vp negative Sadoff adults 18-55 J,MedRxiv,2020 years old and Full text elderly >65 Commentary years old in multiple centres in Belgium and the US NCT04400838 Non ChAdOx1 LD/SD 1/2 doses RCT Healthy N=7548 Full University of replicating MenACWY Phase adults in 18 descriptio Oxford/AstraZenec viral ChAdOx1 SD/SD 1/2 doses 2/3 centers in the n a vector MenACWY UK Voysey M (COV002), Lancet, 2020 Full text Commentary ISRCTN89951424 Non ChAdOx1 SD/SD MenACWY/salin RCT Healthy N=4088 Full 3 University of replicating e Phase SARS-CoV-2 descriptio Oxford/AstraZenec viral 3 serology/DNA n a vector negative Voysey M adults in six (COV003), Lancet, centres in 2020 Brazil Full text Commentary NCT04444674 Non ChAdOx1 std 2 Saline RCT Healthy N=2013 Full University of replicating doses Phase adults from descriptio Oxford/AstraZenec viral 1/2 four studies in n a vector multiple Voysey M centres in (COV005), Lancet, Brazil, South 2020 Africa, and the UK Full text Commentary NCT04368728 RNA BNT162b1 10 Placebo RCT Healthy N=195 Full BioNTech SE, based mcg D1/21 Phase SARS-CoV-2 descriptio Pfizer vaccine BNT162b1 20 Placebo 1 serology/DNA n Walsh E, N Engl J mcg D1/21 negative Med, 2020 BNT162b1 30 Placebo adults in four Full text mcg D1/21 centres in Commentary BNT162b1 100 Placebo USA mcg D1/21 BNT162b2 10 Placebo mcg D1/21 BNT162b2 20 Placebo mcg D1/21 BNT162b2 30 Placebo mcg D1/21 ChiCTR200003180 Inactivate Inactivated Adjuvant RCT Healthy N=96 Full 9 d virus 2.5mcg-D0/28/56 Phase adults, aged descriptio Wuhan Institute of Inactivated 5mcg- Adjuvant 1/2 18 to 59 n Biological Products D0/28/56 years, w ithout Co Ltd./Sinopharm Inactivated Adjuvant history Xia S, JAMA, 2020 10mcg-D0/28/56 ofSARS- Full text Inactivated 5mcg- Adjuvant CoV(via on- Commentary D0/14 site inquiry) Inactivated 5mcg- Adjuvant or SARS- D0/21 CoV-2 infection (via serologicalan d nucleic acid test ChiCTR200003245 Inactivate BBIBP-CorV Adjuvant RCT Healthy N=112 Full 9 d virus 8mcg Phase SARS-CoV-2 descriptio Beijing Institute of BBIBP-CorV Adjuvant 2 serology n Biological 4mcg D0/14 negative Products/Sinophar BBIBP-CorV Adjuvant adults 18-59 m 4mcg D0/21 years old and Xia S, Lancet Infect BBIBP-CorV Adjuvant ?60 years old Dis, 2020 4mcg D0/28 in a single Full text centre in Commentary China NCT04352608 Inactivate CoronaVac 3 Adjuvant RCT Healthy N=600 Full Sinovac d virus mcg D0/14 Phase SARS-CoV-2 descriptio Zhang Y,Lancet CoronaVac 6 Adjuvant 2 serology/DNA n Infect Dis,2020 mcg D0/14 negative Full text CoronaVac 3 Adjuvant adults in a Commentary mcg D0/28 single centre 4 CoronaVac 6 Adjuvant in China mcg D0/28 NCT04341389 Non Adenovirus type- Placebo RCT Healthy adult N=508 Full CanSino Biological replicating 5-vectored Phase volunteers descriptio Inc./Beijing Institute viral COVID-19 1 × 2 w ith HIV- n of Biotechnology vector 10¹¹ vp negative and Zhu F, The Lancet, SARS-CoV-2 2020 infection-free Full text in a single Commentary centre in Commentary China. ARTICLES Note: References are sorted by year (newest to oldest) 1. Marian AJ. Current state of vaccine development and targeted therapies for COVID-19: impact of basic science discoveries. Cardiovasc Pathol. 2021;50:107278. DOI: 10.1016/j.carpath.2020.107278 ABSTRACT: Coronavirus disease-19 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is closely related to two other coronaviruses that caused disease epidemic breakouts in humans in the last 2 decades, namely, severe acute respiratory distress syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV).
Load more

Recommended publications
  • 23 April 2020 Update
    20 April – 23 April 2020 Contents I. Summary .............................................................................................................................1 II. European Union .................................................................................................................5 III. France ...............................................................................................................................6 IV. Italy ...................................................................................................................................7 V. Germany ............................................................................................................................8 VI. Spain ...............................................................................................................................10 VII. United Kingdom .............................................................................................................10 I. SUMMARY Number of cases: 1,009,762 (including the UK) Number of deaths: 108,223 • The EU Executive Steering Group on Shortages of Medicines Caused by Major Events held a meeting on 15 April to discuss the progress of the measures regarding availability of medicines for European patients during the COVID-19 pandemic. They also updated the Q&A document on regulatory expectations for medicinal products for human use during the COVID-19 pandemic on 20 April. On 21 April, they set-up the fast-track system to support essential medicines for COVID-19 treatment,
    [Show full text]
  • Written Evidence from Spotlight on Corruption1 (PGG18) the Public
    Written evidence from Spotlight on Corruption1 (PGG18) The Public Administration and Constitutional Affairs Committee Propriety of governance in light of Greensill inquiry Introduction The revelations arising from the Greensill affair and its fallout, coming alongside other recent and ongoing scandals, have exposed significant weaknesses in the UK system for managing conflicts of interest, lobbying, and business appointments. This is a vital opportunity to bring the UK’s standards landscape up to date, and to ensure that integrity and ethics in government are regulated in a way that befits a modern democracy. Taking action to strengthen the UK’s integrity and ethics framework would benefit the UK by helping to: build trust in politicians and government; strengthen the stability, predictability and attractiveness of the UK as a place to do business; give the UK greater credibility on the international stage in promoting democracy and good governance; and implement outstanding recommendations made by international bodies such as the UN and Council of Europe about how the UK can improve its integrity and ethics framework to prevent and tackle corruption. Key Recommendations 1. Integrity and Ethics legislation. The government should consult on the introduction of an Integrity and Ethics Bill, by the spring of 2022, which gives legislative effect to: the Law Commission’s recommendations on the introduction of a corruption in public office offence; recommendations made by international bodies to put ACOBA and the Independent Advisor on Ministerial Interests on a statutory footing; recommendations that are likely to be made by the Committee on Standards in Public Life’s Standards Matters 2.0 review in the Autumn of 2021; and recommendations likely to be made from both the Boardman review and parliamentary committees such as PACAC, including legislative reform to the Lobbying Act.
    [Show full text]
  • UK COVID-19 Vaccines Delivery Plan
    UK COVID-19 vaccines delivery plan Published 11 January 2021 Contents 1. Ministerial foreword ....................................................................................................... 3 2. Executive summary and scope ..................................................................................... 4 Supply .............................................................................................................................. 5 Prioritisation ...................................................................................................................... 6 Places ............................................................................................................................... 7 People .............................................................................................................................. 8 Tracking our progress ....................................................................................................... 9 3. Supply ......................................................................................................................... 10 Developing new vaccines ............................................................................................... 10 Ensuring vaccines meet strict safety standards for deployment ..................................... 17 Building UK manufacturing capability ............................................................................. 21 4. Prioritisation ...............................................................................................................
    [Show full text]
  • COVID-19 Interim Vaccination Plan V.5 Pennsylvania
    COVID-19 Interim Vaccination Plan V.5 Pennsylvania PA COVID-19 Vaccine Task Force/PA Department of Health JANUARY 19, 2021 |VERSION 5.0 PENNSYLVANIA COVID-19 INTERIM VACCINATION PLAN Table of Contents Introduction……………………………………………………………………………………………………………………………………….2 Section 1: COVID-19 Vaccination Preparedness Planning ......................................................................... 3 Section 2: COVID-19 Organizational Structure and Partner Involvement ................................................. 4 Section 3: Phased Approach to COVID-19 Vaccination ........................................................................... 11 Section 4: Critical Populations ................................................................................................................. 17 Section 5: COVID-19 Provider Recruitment and Enrollment ................................................................... 21 Section 6: COVID-19 Vaccine Administration Capacity ........................................................................... 25 1. Health and Medical Infrastructure .......................................................................................... 25 2. Occupational Health Clinics and Closed Points of Dispensing (PODs) ..................................... 26 3. Expanded Outreach to Ensure Vaccine Access ........................................................................ 27 4. Staffing ....................................................................................................................................
    [Show full text]
  • Role and Responsibilities of the Chair of the Vaccine Taskforce
    Chair of the Vaccine Taskforce Information pack for applicants Closing date: Midday on Friday 14 May 2021 Reference no: VAC-1775 Follow us on Twitter @appointmentsdh Table of Contents Section 1: Role, responsibilities and person specification.................................................... 2 Section 2: How to apply ....................................................................................................... 4 2.1 Making an application ............................................................................................. 4 2.2 The selection process ............................................................................................. 7 2.3 Eligibility criteria ...................................................................................................... 9 2.4 How we will manage your personal information .................................................... 10 Chair of the Vaccine Taskforce - Information pack for applicants Section 1: Role and responsibilities of the Chair of the Vaccine Taskforce The Chair must enable the Vaccine Taskforce to achieve their three core objectives during the pandemic period: a. To secure access to promising vaccine/s for the UK population. b. To make provision for international distribution of vaccines. c. To strengthen the UK’s onshore capacity and capability in vaccine development, manufacturing, and supply chain to provide resilience for this and future pandemics. In recognising that the Taskforce has now been in existence for over a year, delivering these objectives
    [Show full text]
  • WHO Backs Rollout of Astrazeneca Vaccine
    this week TWINS page 423 • VACCINATING CHILDREN page 424 • BRITISH CYCLING page 427 FRANK HOERMANN/DPA/PA/ALAMY FRANK WHO backs rollout of AstraZeneca vaccine Doctors have warned of the risks associated On 16 March WHO’s chief scientist, Soumya The World Health Organization with pausing or delaying vaccination Swaminathan, said, “We do not want has urged people not to panic programmes against covid-19, as the people to panic, and we would, for the time amid reports of blood clotting number of European countries that have being, recommend that countries continue disorders in patients receiving the vaccine halted use of the Oxford University and vaccinating with AstraZeneca . So far, we AstraZeneca vaccine rose to 16. do not fi nd an association between these Denmark, Norway, Bulgaria, Iceland, events and the vaccine.” France, Germany, Italy, Spain, Portugal, The EMA said there had been 30 reports Slovenia, and Cyprus have suspended all of thromboembolic events among nearly use of the vaccine. Five other countries fi ve million people given the AstraZeneca (Austria, Estonia, Latvia, Lithuania, and vaccine in the European Economic Area. Luxembourg) have paused the use of a AstraZeneca has said 37 blood clots have LATEST ONLINE batch of a million doses of the vaccine. been reported among more than 17 million NHS and social The moves came after reports of people vaccinated in the EU and Britain. care need an extra blood clotting disorders. The Norwegian Five of the cases were deep vein thrombosis, £12bn to get back Medicines Agency said last week it was and 22 were pulmonary embolisms.
    [Show full text]
  • UKC Monthly Summary 2020 July.Odt
    UK COLUMN CONTENT – July 2020 https://www.ukcolumn.org/ukcolumn-news-archive 01st July 2020 Brian Gerrish and Mike Robinson with today's UK Column News. START – Good news: excess mortality rate falls below five-year average Leicester local lockdown – police to spot-check cars leaving the restricted zone… Government provides details without showing any evidence to support them SAGE recommended ramping up fear and turning communities against each other The Ferguson effect: a similar situation occurred with Foot & Mouth – community division This policy seems deliberate by the UK ‘government of occupation’ Increased Covid-19 testing will obviously result in an increase in reported cases Is this a trial run and normalisation of ‘City State’ powers…? CoronaVirus found in waste water as early as March 2019 in Spain The spike in excess deaths across the world happened after lockdown… 15:49 – More fear: schools, hospitals and offices told to prepare for ‘marauding’ terror attacks Mail Online: is your teen secretly struggling with depression…? Mail Online: workers’ health starts to fail at the age of 59 MSM complains about Covid-19 infodemic – the ‘wrong’ kind of information… 19:28 – David Noakes (GcMAF) contact information CoronaVirus: Upper Crust owner blames lockdown for 5,000 UK redundancies Michael Gove quotes Franklin Delano Roosevelt in Brexit comments Gove suggests that change is coming to the UK Civil Service Boris announces a ‘new deal’ - ‘the opportunity is massive’ The MainStream Media reaction to Boris…? Nothing, silence… MSM too busy
    [Show full text]
  • MCC VA COVID-19 Vaccine Provider FAQ May 2021
    COVID-19 Vaccine Provider FAQs We are actively monitoring COVID-19 vaccine developments. Below you will find helpful information and answers to some of the most frequently asked questions about COVID-19 vaccines. Magellan Complete Care has a COVID-19 Vaccine Taskforce comprised of experts, including clinicians, health plan leadership, and pharmacy network team members that meets regularly to discuss the latest developments and plan support. We are monitoring government guidance at the federal and state levels. We are taking steps to ensure you have the information you need as the information and guidelines are made available by federal and state agencies. Vaccine Development and Distribution Operation Warp Speed (OWS) was set up by the White House to coordinate efforts among federal government entities, states, and private sector partners. It aims to accelerate the testing, supply, development, and distribution of safe and effective vaccines, therapeutics, and diagnostics. There are many government agencies involved in helping with the COVID-19 pandemic. A few of the key agencies are listed below for your reference: • Food and Drug Administration (FDA) – The FDA reviews and approves or authorizes safe and effective vaccines. • Centers for Disease Control and Prevention (CDC) – The CDC is responsible for controlling the introduction and spread of infectious diseases. • Advisory Committee on Immunization Practices (ACIP) – ACIP is a committee within the CDC that provides advice and guidance on effective control of vaccine-preventable diseases in the U.S. civilian population. • National Academies of Science Engineering & Medicine (NASEM) – The National Institutes of Health (NIH) and CDC have tasked NASEM to develop a plan for equitable allocation of vaccines.
    [Show full text]
  • COVID-19 Vaccine Priority Strategy Using a Heterogenous Transmission Model Based on Maximum Likelihood Estimation in the Republic of Korea
    International Journal of Environmental Research and Public Health Article COVID-19 Vaccine Priority Strategy Using a Heterogenous Transmission Model Based on Maximum Likelihood Estimation in the Republic of Korea Youngsuk Ko 1 , Jacob Lee 2, Yeonju Kim 3, Donghyok Kwon 3 and Eunok Jung 1,* 1 Department of Mathematics, Konkuk University, Seoul 05029, Korea; [email protected] 2 Division of Infectious Disease, Department of Internal Medicine, Hallym University College of Medicine, Chuncheon 24252, Korea; [email protected] 3 Division of Public Health Emergency Response Research, Korea Disease Control and Prevention Agency, Cheongju 28159, Korea; [email protected] (Y.K.); [email protected] (D.K.) * Correspondence: [email protected] Abstract: (1) Background: The vaccine supply is likely to be limited in 2021 due to constraints in manufacturing. To maximize the benefit from the rollout phase, an optimal strategy of vaccine allocation is necessary based on each country’s epidemic status. (2) Methods: We first developed a heterogeneous population model considering the transmission matrix using maximum likelihood estimation based on the epidemiological records of individual COVID-19 cases in the Republic of Korea. Using this model, the vaccine priorities for minimizing mortality or incidence were investigated. (3) Results: The simulation results showed that the optimal vaccine allocation strategy to minimize the mortality (or incidence) was to prioritize elderly and healthcare workers (or adults) as Citation: Ko, Y.; Lee, J.; Kim, Y.; long as the reproductive number was below 1.2 (or over 0.9). (4) Conclusion: Our simulation results Kwon, D.; Jung, E. COVID-19 Vaccine support the current Korean government vaccination priority strategy, which prioritizes healthcare Priority Strategy Using a workers and senior groups to minimize mortality, under the condition that the reproductive number Heterogenous Transmission Model remains below 1.2.
    [Show full text]
  • Whole Day Download the Hansard
    Tuesday Volume 678 30 June 2020 No. 78 HOUSE OF COMMONS OFFICIAL REPORT PARLIAMENTARY DEBATES (HANSARD) Tuesday 30 June 2020 © Parliamentary Copyright House of Commons 2020 This publication may be reproduced under the terms of the Open Parliament licence, which is published at www.parliament.uk/site-information/copyright/. 133 30 JUNE 2020 134 Wendy Morton: That is a really important point. The House of Commons Prime Minister has made it clear that equitable access is an integral part of the UK’s approach to vaccine Tuesday 30 June 2020 development and distribution. Only last weekend, he emphasised how all the world’s leaders have a moral duty to ensure that covid-19 vaccines are truly available The House met at half-past Eleven o’clock to all. That is why the UK has contributed more than £313 million of UK aid to CEPI, the COVID-19 PRAYERS Therapeutics Accelerator, the Access to COVID-19 Tools (ACT) Accelerator, and the Foundation for Innovative New Diagnostics. We have also committed £1.65 billion [MR SPEAKER in the Chair] to Gavi over five years to strengthen immunisation for Virtual participation in proceedings commenced (Order, vaccine preventable disease in vulnerable countries. 4 June). Andrew Jones: Around the world, there are more than [NB: [V] denotes a Member participating virtually.] 100 programmes to develop a coronavirus vaccine. Can my hon. Friend confirm that our global diplomatic presence is assisting UK companies and universities to Oral Answers to Questions participate in those programmes, basically by using their local networks to highlight the significant expertise that the UK can contribute, but also vice versa to identify where those contacts can contribute to UK-based FOREIGN AND COMMONWEALTH OFFICE programmes, because this is truly a global effort? The Secretary of State was asked— Wendy Morton: Yes, our overseas network is working actively around the globe, particularly through our Covid-19 Vaccine world-leading science and innovation network.
    [Show full text]
  • COVID-19 Vaccine Faqs from Piedmont Healthcare
    January 7, 2021 Piedmont’s Vaccine Taskforce FAQs In response to a request from the State, Piedmont has created a cross functional, system-level taskforce to create a plan for how we will assist in deploying a COVID-19 vaccine. Our deployment is in accordance State and Federal agency guidelines. Below are FAQs the Taskforce has developed for all of our stakeholders – patients and workforce members. Use the links below to navigate to various sections of this document. General COVID-19 Vaccine Questions ................................................................................................................................................... 2 Vaccine Development and Availability ............................................................................................................................................ 2 Vaccine Benefits ............................................................................................................................................................................ 2 Vaccine Safety and Efficacy ........................................................................................................................................................... 3 Manufacturer specific vaccine information ...................................................................................................................................... 3 Vaccine Considerations in Special Populations .............................................................................................................................
    [Show full text]
  • Legal-Graphics' 6-26-21 COVID Timeline
    Number of days since first sign of virus Overview: Year 2 of COVID Year 2 Nov. 23, 2020 Dec. 3, 2020 Dec. 11, 2020 Dec. 21, 2020 Dec. 30, 2020 Jan. 7, 2021 Jan.Jan. 14,7, 2021 2021 of COVID-19 Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Coronavirus Deaths Coronavirus Deaths Coronavirus Deaths Coronavirus Deaths Coronavirus Deaths Coronavirus Deaths Coronavirus Deaths over 1,400,000 over 1,500,000 over 1,600,000 over 1,700,000 over 1,800,000 over 1,900,000 over 1,900,0002,000,000 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 Link to Nov. 16, 2020 Nov. 18, 2020 Nov. 21, 2020 Nov. 25, 2020 Nov. 27, 2020 Nov. 30, 2020 Dec. 3, 2020 Dec. 6, 2020 Dec. 8, 2020 Dec. 11, 2020 Dec. 14, 2020 Dec. 17, 2020 Dec. 21, 2020 Dec. 22, 2020 Dec. 26, 2020 Dec. 29, 2020 Dec. 31, 2020 Jan. 3, 2021 Jan. 5, 2021 Jan. 8, 2021 Jan. 11, 2021 Jan. 13, 2021 Jan. 17, 2021 Source Moderna says data FDA allows US cases top Picture of US Demand for live Moderna to request Map showing US UK gears up for Chart of cumulative Pfizer vaccine to be How do the Pfizer Vaccinations reach How the Pfizer Vaccines across Could AZD7442 Map showing How vaccinations Interactive US Map It’s lockdown No.
    [Show full text]